Day One Biopharmaceutical...

NASDAQ: DAWN · Real-Time Price · USD
6.76
0.51 (8.16%)
At close: Aug 15, 2025, 3:59 PM
6.75
-0.15%
After-hours: Aug 15, 2025, 04:10 PM EDT

Day One Biopharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
131.16M n/a n/a n/a
Cost of Revenue
5.28M 383K 531K 199K
Gross Profit
125.88M -383K -531K -199K
Operating Income
-217.27M -206.06M -146.91M -72.74M
Interest Income
19.7M 17.19M 4.75M 4K
Pretax Income
-88.35M -188.92M -142.18M -72.75M
Net Income
-95.5M -188.92M -132.18M -70.44M
Selling & General & Admin
115.45M 75.54M 61.29M 29.16M
Research & Development
227.7M 130.52M 85.62M 43.58M
Other Expenses
n/a n/a -18K -15K
Operating Expenses
343.15M 206.06M 146.91M 72.74M
Interest Expense
n/a n/a 4.75M 4K
Selling & Marketing Expenses
83.9M n/a n/a n/a
Cost & Expenses
348.43M 206.06M 146.91M 72.74M
Income Tax Expense
-7.14M n/a -10.01M n/a
Shares Outstanding (Basic)
93.62M 79.77M 65.47M 61.95M
Shares Outstanding (Diluted)
93.62M 79.77M 65.47M 61.95M
EPS (Basic)
-1.02 -2.37 -2.02 -1.14
EPS (Diluted)
-1.02 -2.37 -2.02 -1.14
EBITDA
-217.27M -206.06M -141.65M -72.56M
EBIT
-88.35M -206.06M -146.91M -72.75M
Depreciation & Amortization
2.03M 383K 531K 199K